Choose your injection device without delaying the drug program.
Existing platform or new development, settled before the choice costs you time.
Sound familiar?
A filing date set in stone?
Units on time for the pivotal study.
A platform for the pipeline?
One device for this drug and the pipeline.
Everyone has an opinion?
One clear rationale everyone can follow.
Tough competition?
Differentiate through the device.
Too many platforms?
Deep platform knowledge to narrow it down.
Three directions. One decision.
Each direction is laid out in timeline, cost and risk, so the trade-offs are visible and the choice is yours, on a basis you can defend.
Existing platform or new development. Each with timeline, cost, risk and the margin it gives to the program's milestones, such as clinical units for the pivotal study.
Each candidate is scored on four axes: time to filing-ready, risk, new resources and future options. The assessment of time and risk rests on how mature each supplier's setup is, not on full quotations, which take longer than the scoping. Covers pens, autoinjectors and on-body injectors; prefilled syringes with specialist partners.
The ranked shortlist, the scorecard and the recommendation, ready to present.
The path to market for the combination product, the screening of platforms and the scorecard for the 2–4 strongest candidates, documented.
For the strongest candidates: market performance (MAUDE, FAERS), what the supplier delivers beyond the device, time to clinical units, IP and sustainability. Priced as an add-on.
Handed over in a session with your team.
How we work
Four steps from the first question to a decision you can defend.
Ambition and assumptions
Drug, patients, administration, dosing and market, and the drugs that may follow on the same platform.
The path to market
Every activity and resource the combination product requires, on one map: the critical path, and what you need in-house versus from partners. From here, all functions talk about the same choice. The specification follows: container, volume, viscosity, maturity and supply chain.
Screening
The platforms on the market and in development are screened on technical compatibility, maturity and intended use fit, down to the 2–4 strongest candidates. The optional deep dive starts here.
Decision platform
Three directions, shortlist and recommendation, walked through with your team.
About 9 weeks in total. The plan is confirmed with you in step 1.
An estimate, not a quote.
Four weeks assumes the data is ready at the start and the right people are available when needed.
See it in practice
Platform or new development
Which devices does Injection Device Selection cover?
Pens, autoinjectors and on-body injectors. Prefilled syringes with specialist partners.
Does Skibla sell a platform?
No. Skibla is not tied to any supplier and sells no platform.
Who makes the final choice?
You do, on a basis you can defend.
How long does it take?
From about 4 weeks when most is already known, to about 14 weeks when little is. The optional deep dive adds time, depending on how many candidates it covers. The plan is confirmed with you in step 1.
What do you need from us?
Data ready at the start, access to the right people at agreed times, and one named owner. That is what makes four weeks possible.
How do we start?
Book a 30-minute call. If you prefer, write to info@skibla.com or call +45 50 30 75 73.
Our guiding principles
Built for tough decisions
Independent, with no platform to sell.
Hands-on, not hands-off
Autoinjector platforms built from scratch.
AI-enabled, human-led
AI screens. Device experts weigh it.